RNA, U4 small nuclear 9, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-9P profile across patient tissues and cancer cell-line models. RNU4-9P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RNU4-9P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RNU4-9P RNA expression shows 6,800 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight TGCT, BRCA, and GBM as cancer lineages where RNU4-9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-9P survival associations across molecular data types. RNU4-9P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-9P RNA expression–survival associations across cancer types. High RNU4-9P expression shows unfavorable associations in TGCT, KIRP, THCA, CHOL and PCPG, but favorable associations in OV. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for RNU4-9P RNA expression.
This table summarizes RNU4-9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-9P shows lower tumor expression in BRCA and LUSC and higher tumor expression in KIRC. The BRCA box plot shows higher RNU4-9P RNA expression in normal versus tumor tissue (log2 FC = −0.129, t-test p = .033).
This table shows molecular features associated with RNU4-9P in patient tissues and cancer cell lines. In patient samples, RNU4-9P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
